Abstract
Introduction: The recent pandemic that has been caused by the novel coronavirus, SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronovirus-2) has led to a huge burden on health, social and economic systems worldwide. There is currently no known cure. The medical fraternity is left to care for large numbers of ill patients using treatments that have not been clinically proven to be effective. The rapid spread of the virus has not allowed for large scale clinical trials to be undertaken and thus most treatment regimens have been based on observational studies. Tocilizumab has shown promise in some reports when used in the hyper inflammatory stage of the disease. Methods: Two patients who were Intensive Care Unit (ICU) requiring were administered 400 mg of Tocilizumab as a single dose after having been diagnosed with features of a Cytokine Release Syndrome. Results: Both patients responded positively with a decrease in symptomatology and inflammatory markers. Conclusion: Patients who present in the hyper-inflammatory stage of SARS-CoV-2 may be considered for Intravenous (IV) Tocilizumab therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
